NO330691B1 - Anvendelse av en sammensetning omfattende et pollenekstrakt for behandling av hormonrelaterte forstyrrelser i forbindelse med menopause hos kvinner samt sammensetning omfattende slikt ekstrakt. - Google Patents
Anvendelse av en sammensetning omfattende et pollenekstrakt for behandling av hormonrelaterte forstyrrelser i forbindelse med menopause hos kvinner samt sammensetning omfattende slikt ekstrakt. Download PDFInfo
- Publication number
- NO330691B1 NO330691B1 NO20030988A NO20030988A NO330691B1 NO 330691 B1 NO330691 B1 NO 330691B1 NO 20030988 A NO20030988 A NO 20030988A NO 20030988 A NO20030988 A NO 20030988A NO 330691 B1 NO330691 B1 NO 330691B1
- Authority
- NO
- Norway
- Prior art keywords
- pollen
- extract
- vitamin
- fem
- active ingredients
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 29
- 239000000203 mixture Substances 0.000 title claims abstract description 23
- 238000011282 treatment Methods 0.000 title claims abstract description 13
- 239000005556 hormone Substances 0.000 title abstract 2
- 229940088597 hormone Drugs 0.000 title abstract 2
- 230000009245 menopause Effects 0.000 title description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 48
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 23
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 23
- 229940046009 vitamin E Drugs 0.000 claims abstract description 23
- 239000011709 vitamin E Substances 0.000 claims abstract description 23
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 23
- 239000004480 active ingredient Substances 0.000 claims abstract description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 17
- 208000035475 disorder Diseases 0.000 claims abstract description 17
- 230000001086 cytosolic effect Effects 0.000 claims abstract description 12
- 229940109850 royal jelly Drugs 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 10
- 235000015110 jellies Nutrition 0.000 claims description 16
- 239000008274 jelly Substances 0.000 claims description 16
- 208000000112 Myalgia Diseases 0.000 claims description 7
- 208000013465 muscle pain Diseases 0.000 claims description 7
- 206010013954 Dysphoria Diseases 0.000 claims description 6
- 206010019233 Headaches Diseases 0.000 claims description 6
- 206010060800 Hot flush Diseases 0.000 claims description 6
- 206010033557 Palpitations Diseases 0.000 claims description 6
- 241000209504 Poaceae Species 0.000 claims description 6
- 206010066218 Stress Urinary Incontinence Diseases 0.000 claims description 6
- 231100000869 headache Toxicity 0.000 claims description 6
- 230000003054 hormonal effect Effects 0.000 claims description 6
- 208000022170 stress incontinence Diseases 0.000 claims description 6
- 229940088594 vitamin Drugs 0.000 claims description 6
- 229930003231 vitamin Natural products 0.000 claims description 6
- 235000013343 vitamin Nutrition 0.000 claims description 6
- 239000011782 vitamin Substances 0.000 claims description 6
- 208000006820 Arthralgia Diseases 0.000 claims description 5
- 241000196324 Embryophyta Species 0.000 claims description 5
- 206010022998 Irritability Diseases 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 210000004400 mucous membrane Anatomy 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 230000035900 sweating Effects 0.000 claims description 5
- 208000008454 Hyperhidrosis Diseases 0.000 claims description 4
- 206010027951 Mood swings Diseases 0.000 claims description 4
- 210000004379 membrane Anatomy 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 150000008442 polyphenolic compounds Chemical class 0.000 claims description 4
- 235000013824 polyphenols Nutrition 0.000 claims description 4
- 235000018553 tannin Nutrition 0.000 claims description 4
- 229920001864 tannin Polymers 0.000 claims description 4
- 239000001648 tannin Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 206010016807 Fluid retention Diseases 0.000 claims description 3
- 229940093797 bioflavonoids Drugs 0.000 claims description 3
- 235000021466 carotenoid Nutrition 0.000 claims description 3
- 150000001747 carotenoids Chemical class 0.000 claims description 3
- 229940088598 enzyme Drugs 0.000 claims description 3
- 229940106582 estrogenic substances Drugs 0.000 claims description 3
- JKKFKPJIXZFSSB-CBZIJGRNSA-N estrone 3-sulfate Chemical compound OS(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 JKKFKPJIXZFSSB-CBZIJGRNSA-N 0.000 claims description 3
- 230000036651 mood Effects 0.000 claims description 3
- 235000013619 trace mineral Nutrition 0.000 claims description 3
- 239000011573 trace mineral Substances 0.000 claims description 3
- 208000033830 Hot Flashes Diseases 0.000 claims description 2
- 229930003935 flavonoid Natural products 0.000 claims 1
- 235000017173 flavonoids Nutrition 0.000 claims 1
- 150000002215 flavonoids Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 230000000694 effects Effects 0.000 description 11
- 102000019197 Superoxide Dismutase Human genes 0.000 description 6
- 108010012715 Superoxide dismutase Proteins 0.000 description 6
- 239000003163 gonadal steroid hormone Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 208000017657 Menopausal disease Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 206010036618 Premenstrual syndrome Diseases 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 208000019116 sleep disease Diseases 0.000 description 3
- 208000022925 sleep disturbance Diseases 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 238000001794 hormone therapy Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 241000256837 Apidae Species 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 1
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 1
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 description 1
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 206010048908 Seasonal allergy Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 229930003571 Vitamin B5 Natural products 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000021196 dietary intervention Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000027720 dry mucous membrane Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- -1 glidants Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 201000004338 pollen allergy Diseases 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000009492 vitamin B5 Nutrition 0.000 description 1
- 239000011675 vitamin B5 Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Reproductive Health (AREA)
- Insects & Arthropods (AREA)
- Microbiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Anesthesiology (AREA)
- Mycology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0003092A SE0003092D0 (sv) | 2000-09-01 | 2000-09-01 | New Use |
| PCT/SE2001/001851 WO2002017944A1 (en) | 2000-09-01 | 2001-08-31 | Use of a composition comprising an extract of pollen for the treatment of hormonally-related disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20030988D0 NO20030988D0 (no) | 2003-03-03 |
| NO20030988L NO20030988L (no) | 2003-03-03 |
| NO330691B1 true NO330691B1 (no) | 2011-06-14 |
Family
ID=20280860
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20030988A NO330691B1 (no) | 2000-09-01 | 2003-03-03 | Anvendelse av en sammensetning omfattende et pollenekstrakt for behandling av hormonrelaterte forstyrrelser i forbindelse med menopause hos kvinner samt sammensetning omfattende slikt ekstrakt. |
Country Status (10)
| Country | Link |
|---|---|
| EP (5) | EP1313496B1 (de) |
| JP (5) | JP2004507509A (de) |
| AT (5) | ATE283060T1 (de) |
| AU (7) | AU8281401A (de) |
| CA (5) | CA2424026A1 (de) |
| DE (5) | DE60107441D1 (de) |
| NO (1) | NO330691B1 (de) |
| PL (1) | PL202468B1 (de) |
| SE (1) | SE0003092D0 (de) |
| WO (5) | WO2002017941A1 (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005139150A (ja) * | 2003-11-10 | 2005-06-02 | Api Co Ltd | エストロゲン様作用剤及びその製造方法、並びに骨粗しょう症予防剤及び飲食品 |
| US7887851B2 (en) * | 2004-06-07 | 2011-02-15 | Kao Corporation | Aromatase activator |
| CN104027100A (zh) * | 2014-06-12 | 2014-09-10 | 山东中弘信息科技有限公司 | 一种基于最近历史值的血压异常数据处理方法 |
| KR101533197B1 (ko) * | 2014-09-18 | 2015-07-02 | 성균관대학교산학협력단 | 부테인을 포함하는 부종의 예방 또는 치료용 조성물 |
| FR3055215B1 (fr) * | 2016-08-31 | 2020-02-14 | S.A.M. Serelys Pharma | Composition comprenant des extraits de pollen et /ou de pistils |
| CN106138856A (zh) * | 2016-09-30 | 2016-11-23 | 四川易创生物科技有限公司 | 一种治疗经间期出血的新型中药组合物及制备方法 |
| EP3335717A1 (de) * | 2016-12-13 | 2018-06-20 | Serelys Pharma S.A.M. | Zusammensetzung zur verwendung bei der behandlung von symptomen im zusammenhang mit prämenstruellem syndrom (pms) |
| FR3070263B1 (fr) | 2017-08-28 | 2020-07-24 | Serelys Pharma S A M | Composition pour son utilisation dans le traitement et/ou la prevention de l’infertilite |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2970957B2 (ja) * | 1991-05-15 | 1999-11-02 | 株式会社グレイトチレン | 精製花粉栄養調整物 |
| ES2081255B1 (es) * | 1994-01-05 | 1996-09-01 | Ind Farma Especial | Aplicacion de las proteinas receptoras de autoincompatibilidad (slsg) de plantas para el tratamiento de las enfermedades alergicas. |
| US5569459A (en) * | 1995-02-15 | 1996-10-29 | Bio-Virus Research Incorporated | Pharmaceutical compositions for the management of premenstrual syndrome and alleviation of menopausal disorders |
| JPH09278665A (ja) * | 1996-04-10 | 1997-10-28 | Api Kk | 花粉エキスソフトカプセル剤及びその製造方法 |
| DE69935206T2 (de) * | 1998-02-23 | 2007-10-31 | Taiyo Kagaku Co., Ltd., Yokkaichi | Theanin-beinhaltende zusammenstellung |
-
2000
- 2000-09-01 SE SE0003092A patent/SE0003092D0/xx unknown
-
2001
- 2001-08-31 JP JP2002522916A patent/JP2004507509A/ja active Pending
- 2001-08-31 DE DE60107441T patent/DE60107441D1/de not_active Expired - Lifetime
- 2001-08-31 DE DE60107442T patent/DE60107442D1/de not_active Expired - Lifetime
- 2001-08-31 CA CA002424026A patent/CA2424026A1/en not_active Abandoned
- 2001-08-31 AU AU8281401A patent/AU8281401A/xx active Pending
- 2001-08-31 DE DE60108402T patent/DE60108402D1/de not_active Expired - Lifetime
- 2001-08-31 AT AT01961557T patent/ATE283060T1/de not_active IP Right Cessation
- 2001-08-31 EP EP01963652A patent/EP1313496B1/de not_active Expired - Lifetime
- 2001-08-31 JP JP2002522917A patent/JP4896354B2/ja not_active Expired - Lifetime
- 2001-08-31 WO PCT/SE2001/001848 patent/WO2002017941A1/en active IP Right Grant
- 2001-08-31 AT AT01961555T patent/ATE283059T1/de not_active IP Right Cessation
- 2001-08-31 WO PCT/SE2001/001850 patent/WO2002017943A1/en active IP Right Grant
- 2001-08-31 AU AU2001282814A patent/AU2001282814B2/en not_active Expired
- 2001-08-31 EP EP01961554A patent/EP1313492B1/de not_active Expired - Lifetime
- 2001-08-31 WO PCT/SE2001/001847 patent/WO2002017940A1/en active IP Right Grant
- 2001-08-31 EP EP01961555A patent/EP1313493B1/de not_active Expired - Lifetime
- 2001-08-31 EP EP01961557A patent/EP1313495B1/de not_active Expired - Lifetime
- 2001-08-31 AU AU2001284581A patent/AU2001284581B2/en not_active Ceased
- 2001-08-31 CA CA002424011A patent/CA2424011A1/en not_active Abandoned
- 2001-08-31 DE DE60107444T patent/DE60107444T2/de not_active Expired - Lifetime
- 2001-08-31 CA CA2420906A patent/CA2420906C/en not_active Expired - Lifetime
- 2001-08-31 JP JP2002522913A patent/JP2004507506A/ja active Pending
- 2001-08-31 WO PCT/SE2001/001849 patent/WO2002017942A1/en active IP Right Grant
- 2001-08-31 EP EP01961556A patent/EP1313494B1/de not_active Expired - Lifetime
- 2001-08-31 WO PCT/SE2001/001851 patent/WO2002017944A1/en active IP Right Grant
- 2001-08-31 PL PL360652A patent/PL202468B1/pl unknown
- 2001-08-31 AT AT01961554T patent/ATE283058T1/de not_active IP Right Cessation
- 2001-08-31 AT AT01963652T patent/ATE283061T1/de not_active IP Right Cessation
- 2001-08-31 AU AU2001282815A patent/AU2001282815A1/en not_active Abandoned
- 2001-08-31 AU AU2001282813A patent/AU2001282813A1/en not_active Abandoned
- 2001-08-31 AU AU2001282816A patent/AU2001282816A1/en not_active Abandoned
- 2001-08-31 JP JP2002522915A patent/JP2004507508A/ja active Pending
- 2001-08-31 JP JP2002522914A patent/JP2004507507A/ja active Pending
- 2001-08-31 AU AU8458101A patent/AU8458101A/xx active Pending
- 2001-08-31 CA CA2420823A patent/CA2420823C/en not_active Expired - Lifetime
- 2001-08-31 CA CA002424146A patent/CA2424146A1/en not_active Abandoned
- 2001-08-31 DE DE60107443T patent/DE60107443D1/de not_active Expired - Lifetime
- 2001-08-31 AT AT01961556T patent/ATE286739T1/de not_active IP Right Cessation
-
2003
- 2003-03-03 NO NO20030988A patent/NO330691B1/no not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RO122659B1 (ro) | Formulare farmaceutică pe bază de sare de calciu şi extract vegetal uscat, procedeu de preparare şi utilizare a acesteia | |
| NO330691B1 (no) | Anvendelse av en sammensetning omfattende et pollenekstrakt for behandling av hormonrelaterte forstyrrelser i forbindelse med menopause hos kvinner samt sammensetning omfattende slikt ekstrakt. | |
| AU2001282814A1 (en) | Use of a composition comprising an extract of pollen for the treatment of irritability | |
| AU2001284581A1 (en) | Use of a composition comprising an extract of pollen for the treatment of edema | |
| US6569471B2 (en) | Method for the treatment of symptoms related to normal hormonal variations in women | |
| RU2736997C1 (ru) | Средство для лечения приливов и восстановления менструального цикла в период перименопаузы и способ его применения | |
| NO330158B1 (no) | Anvendelse av xantofyller | |
| US20030161890A1 (en) | Method of treatment | |
| US20230381263A1 (en) | Multicomponent composition and use thereof in the treatment of prostate diseases | |
| OA20806A (fr) | Complément alimentaire à base de plantes médicinales pour les troubles de la fécondité, les disfonctionnements érectiles et autres affections. | |
| CN104069067B (zh) | 一种防治缺血性心脑血管疾病的豆腐果苷干混悬剂及其制备方法与应用 | |
| KR20210085672A (ko) | 순결나무 추출물을 함유하는 조성물 | |
| Melon | Dietary Supplements for Diabetes: An Evaluation of Commonly Used Products |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: SAM SERELYS PHARMA, MC |
|
| MM1K | Lapsed by not paying the annual fees |